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Original ArticleControl of LDL Uptake in Human Cells
by Targeting the LDLR Regulatory
Long Non-coding RNA BM450697
Roslyn M. Ray,1 Anders Højgaard Hansen,2 Soﬁe Slott,2 Maria Taskova,2 Kira Astakhova,2 and Kevin V. Morris1
1Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute, 1500 E. Duarte Rd., Duarte,
CA, 91010, USA; 2Department of Chemistry, Technical University of Denmark, 206 Kemitorvet, 2800 Kgs Lyngby, DenmarkHypercholesterolemia is a condition that is characterized by
very high levels of cholesterol in the blood and is a major
correlating factor with heart disease. Indeed, high levels of
the low-density lipoprotein (LDL) have been causally linked
to the development of atherosclerotic cardiovascular disease
(ASCVD). A method to speciﬁcally reduce cholesterol in the
blood in a long-term, stable manner could prove therapeuti-
cally relevant. Cholesterol is removed from the blood by the
LDL receptor (LDLR) in the liver. Others and we have discov-
ered that a long non-coding RNA (lncRNA; BM450697) func-
tions as an endogenous epigenetic regulator of LDLR and
that the repression of this lncRNA by the action of small inter-
fering RNAs (siRNAs) results in the activation of LDLR. We
found here, through the interrogation of two siRNAs that
can target this lncRNA, both in a transcriptional and post-tran-
scriptional manner, that BM450697 functions as a local scaf-
fold for modulating LDLR transcription. Moreover, we found
that conjugation of a-N-acetylgalactosamine (GalNAc) with
two lncRNA-directed siRNAs allows for direct liver cell target-
ing of this lncRNA and functional enhanced uptake of
cholesterol. Collectively, these data suggest that targeting the
BM450697 lncRNA regulator of LDLR may result in a more
speciﬁc, long-term, targeted approach to regulating cholesterol
in the blood.Received 15 February 2019; accepted 29 May 2019;
https://doi.org/10.1016/j.omtn.2019.05.024.
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Hypercholesterolemia is a condition characterized by high levels of
cholesterol in the blood and is a major factor that correlates with
heart disease. Speciﬁcally, apolipoprotein-B (ApoB)-containing
lipoproteins have been established as the causative agents in the
development of atherosclerotic cardiovascular disease (ASCVD).1
Low-density lipoprotein (LDL) is a member of the ApoB lipopro-
teins,1 and reducing LDL levels in the blood may lead to a
decreased risk of developing ASCVD. LDL blood levels are regu-
lated by the LDL receptor (LDLR) in the liver, where active cycling
of cholesterol from the blood occurs.2,3 Recent ﬁndings have sug-
gested that long non-coding RNAs (lncRNAs) play an increasingly
important role in cholesterol and lipid homeostasis. lncRNAs are
non-coding transcripts that are over 200 nt in length and have
been shown to modulate transcription or translation in a myriad264 Molecular Therapy: Nucleic Acids Vol. 17 September 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpof ways.4,5 For example, lncRNAs have been shown to modulate
transcription through the recruitment of chromatin remodelling
factors6–8 or by acting as mRNA decoys to sponge away9 or
disrupt transcription factors or transcriptional machinery from
binding to promoter sites10 or as enhancer RNAs to modulate
transcription.11,12 In addition, lncRNAs have been shown to
act as miRNA sponges, modulate splicing events, or alter activa-
tion states of proteins that lead to different transcriptional
outcomes.4,13–15
The modulation of LDL cholesterol occurs via a multi-step
pathway.16,17 One branch of this pathway controls the transcrip-
tion and recycling of the LDLR, whereas the other branch modu-
lates cholesterol biogenesis, and the cross-talk between the
pathways maintains intracellular cholesterol levels.18–20 Several
lncRNAs have been found to participate in the modulation of
cholesterol. For example, the lncRNAs liver-expressed LXR-
induced sequence (LeXis)21 and macrophage-expressed LXR-
induced sequence (MeXis)22 have been found to be integral in
cholesterol biogenesis through modulation of the liver X receptor
(LXR) pathway in mouse hepatocytes and macrophages, respec-
tively, and both may contribute to the development of atheroscle-
rosis.21,22 Further, overexpression of LeXis, using an adeno-associ-
ated virus (AAV) vector in mice, was found to signiﬁcantly
decrease cholesterol levels, suggesting that lncRNAs may be useful
candidates for cholesterol maintenance.23 Matsui et al.24 found
that small RNAs direct transcriptional gene activation (TGA)
of LDLRs, indicating that a lncRNA is actively involved in
LDLR regulation. This lncRNA (expressed sequence tag [EST]
BM450697) is notably antisense (AS) to the LDLR promoter and
is discordantly regulated relative to the LDLR, suggesting that
this RNA may be an endogenous transcript involved in the direct
regulation of LDLR transcription. Further, Matsui et al.24The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. BM450697 lncRNA Characterization in
Hepatic Carcinoma Cell Lines
(A) A schematic diagram from the UCSC Genome
Browser showing the position of BM450697 relative to the
LDLR gene. (B) BM450697 appears to be equally present
in the nuclear and cytoplasmic fractions. Hep 3B cells
(10 million) were separated into nuclear and cytoplasmic
fractions, using subcellular fractionation for RNA. HULC1
transcripts were used as positive controls for cytoplasmic
expression, and NEAT1 was used as a positive control for
nuclear expression. (C) BM450697 is enriched at the
promoter site of LDLR in Hep 3B cells. Hep 3B cells
(100 million) were harvested and incubated with either 50
biotinylated ASOs toward BM450697 or scrambled con-
trols, overnight at 37C. Thereafter, a ChIRP assay was
performed, the resultant genomic DNA was isolated, and
subsequent qPCR was performed to determine the fold
enrichment of BM450697 at the different promoter sites.
BO, beads only; SCR, scrambled. (D) BM450697 formed
DNA:RNA hybrids over the promoter region of the LDLR
gene. Genomic DNA was isolated from either knockdown
of BM450697 or exogenously added 20 fluorinated
BM450697 in Hep 3B cells after 72 h. Thereafter, 5 mg
DNA was used per immunoprecipitation, in DNA samples
treated with or without RNase H. Student’s t test was
used in (B), comparing cytoplasmic and nuclear fractions
for each gene amplified. Two-way ANOVA with the
post hoc Tukey’s test was used in (C) and (D). *p < 0.05,
**p < 0.01, and ***p < 0.0001.
www.moleculartherapy.orgdetermined that this lncRNA may be a useful therapeutic target for
cholesterol modulation.
To this end, we sought to determine the molecular functioning
of the lncRNA BM450697 to modulate LDLR mRNA levels and
to identify candidate transcriptional-gene-silencing (TGS)-mediated
small interfering RNAs (siRNAs) that may be therapeutically useful
in modulating LDL levels. In addition, we used a-N-acetylgalactos-
amine (GalNAc)-conjugated siRNAs as a delivery tool to directly
target the liver for this siRNA-mediated effect. To determine mech-
anistically the involvement of the lncRNA BM450697 in LDLR
regulation, we both overexpressed and repressed BM450697 expres-
sion. Notably, we found that BM450697 is an active transcriptionalMolecular Therapmodulator of LDLR and that two siRNAs were
observed to repress BM450697 and induce
LDLR expression.
RESULTS
BM450697 Is a lncRNA That Is Located in
Both theNuclear andCytoplasmic Fractions
and Is Enriched at the Promoter of the LDLR
Gene in the Form of DNA:RNA Hybrids
BM450697 is an AS RNA that overlaps the pro-
moter of the LDLR gene according to the
University of California, Santa Cruz (UCSC),
Genome Browser (Figure 1A). According tothe Annolnc database, BM450697 appears to be conserved in pri-
mates, but poorly conserved in vertebrates.25 Previous studies have
observed that AS lncRNAs are functional in controlling the transcrip-
tion of some gene promoters.5,26 Recent studies with the LDLR gene
observed an AS lncRNA BM450697 (Figure 1A) that may be func-
tional in RNA directed activation of LDLR.24 To interrogate this
notion further, we assessed both Hep 3B and Hep G2 cell lines for
the expression of BM450697 by directional RT and qPCR (Fig-
ure S1A). Indeed, we observed that both Hep G2 and Hep 3B liver
cells express BM450697 (Figure S1A), which is AS to the LDLR pro-
moter (Figure 1A). In addition, we ﬁnd using a standard curve
method27 that BM450697 has a low level of expression (around
45 copies/ng) of RNA (Figure S1B) in Hep 3B cells. To furthery: Nucleic Acids Vol. 17 September 2019 265
Figure 2. BM450697 Decreases LDLR mRNA Transcription through
Displacement of Pol II and Possibly SREBP1a at the Promoter Site of LDLR
(A) A schematic of the LDLR promoter shows the position of the SREBP1 response
element (SRE) and the primer sets used to amplify the select genomic regions for
Pol II and SREBP1 binding. Hep 3B cells (2 million) were seeded and transfected
the next day with either 10 nM 20 fluorinated (20F) pyrimidine BM450697 RNA or a
lambda RNA control. Cells were cross-linked and processed for ChIP 48 h after
transfection. (B) Pol II and (C) an SREBP1a ChIP. DNA was amplified with either the
promoter-specific LDLR primer sets shown in (A) or with an off-target control primer
set 8 kb upstream of the LDLR promoter site. Histograms are representative of the
mean ± SEM of two independent experiments, performed in triplicate. One-way
ANOVA with the post hoc Dunnett’s test was performed; **p < 0.01.
Molecular Therapy: Nucleic Acidscharacterize this transcript, we conﬁrmed that BM450697 is mostly
polyadenylated, using poly deoxythymine (dT) magnetic beads to
separate the RNA species (Figure S1C). Cytoplasmic fractionation
showed that BM450697 was localized in both the cytoplasmic and nu-
clear fractions, using the nuclear lncRNA nuclear paraspeckle assem-
bly transcript 1 (NEAT1) and the predominantly cytoplasmic
lncRNA highly upregulated in liver cancer 1 (HULC1) as positive
controls for each fraction (Figure 1B).
We used the chromatin immunoprecipitation by RNA pulldown
(ChIRP) method to identify the loci associated with BM450697 (Fig-
ure 1C). Using several primer sets that tile along the LDLR promoter,
we observed that BM450697 was enriched near the 30 end of the LDLR
promoter near the translational start site (Figure 1C), suggesting that
the transcript directly interacts with the DNA of the LDLR promoter.
In addition, we isolated the RNA fraction from the ChIRP assay to
verify BM450697 pulldown with our AS oligonucleotides (Fig-
ure S1D). These results suggest that BM450697 has a functional
role in the nucleus, by acting as a cis-regulatory lncRNA. The ChIRP
data suggest that BM450697 forms DNA:RNA hybrids at the 30 end of
the LDLR promoter. In order to elucidate whether we had a true
DNA:RNA hybrids, we performed DNA:RNA immunoprecipitation
(DRIP) assays in Hep 3B cells with either exogenously added 20 ﬂuo-266 Molecular Therapy: Nucleic Acids Vol. 17 September 2019rinated (20F) pyrimidine BM450697 RNA or under knockdown con-
ditions with the siRNA p5 that targets BM450697 (see Figure 3). We
found that BM450697 forms DNA:RNA hybrids near the 30 end of the
promoter (Figure 1D), with a signiﬁcant enrichment around the
transcription factor binding site of sterol regulatory element binding
protein (SREBP) and near the transcriptional start site (primer set 4).
Further, these hybrids were lost with either RNase H treatment or
under knockdown conditions. Similarly, we found that exogenously
added BM450697 increased enrichment of these hybrids at the
30 end of the LDLR promoter (Figure 1D). These observations and
those of others24 strongly support the notion that BM450697 is
involved in transcriptional control of LDLR.
BM450697 Modulates LDLR mRNA Levels through
Transcriptional Interference
We sought to determine the mechanism by which BM450697 may
regulate LDLR mRNA levels. Our ChIRP and DRIP assays suggested
that BM450697 binds directly to the LDLR promoter and, based on
our work and that of others,24 has a low level of expression. Thus,
we postulated that BM450697 may act by interfering with transcrip-
tion factor SREBP1a or RNA polymerase II (Pol II) association and/or
binding at the LDLR promoter (Figure 2A). SREBP1a is one of the
main transcription factors that drives LDLR gene expression in the
cholesterol pathway;17thus, disruption of either SREBP1a or Pol II
could result in a loss of LDLR transcription. We therefore performed
chromatin immunoprecipitation (ChIP) assays with SREBP1a and
Pol II (using the antibody toward the catalytically active phosphory-
lated serine 5 Pol II). We observed that when exogenous BM450697
RNA was transfected into Hep 3B cells, Pol II association at the
LDLR promoter was signiﬁcantly less compared with the control
(scrambled, or a control lambda RNA; Figure 2B). Similarly, it ap-
peared as if SREBP1a enrichment at the SREBP1 binding site was
less than the control. However, this observation was not signiﬁcant.
Taken together, these data suggest that BM450697 decreases LDLR
mRNA levels mechanistically by blocking interactions with Pol II
and possibly SREBP1a at the promoter of LDLR.
Repression of BM450697 by Small RNAs Induces the LDLR
Previous observations in studies of promoter regulatory AS lncRNAs
suggest that they can be targeted and repressed by the action of
siRNAs28 and AS oligonucleotides.5,29 Rather than focus on the
TGA of LDLR at the promoter site,24 we designed 10 siRNAs that
could result in the TGS of the lncRNA, which could lead to an in-
crease in LDLR expression, using a previously designed algorithm
that generates siRNAs that target transcriptionally important re-
gions.30 We interrogated the ability to target BM450697 with
siRNAs tiled across the lncRNA (Figures 3A and S2). Relative to
both scrambled controls and an siRNA control (CTRL, 24UU)
from Matsui et al.24 we found that the siRNAs 5 and p5 appeared
to induce LDLR expression (Figure 3B). Notably, the previously
described LDLR activating siRNA (24UU, CTRL) and the siRNAs 5
and p5 all demonstrated activation of LDLR in both Hep G2 and
Hep 3B cells (Figure 3B). Interestingly, p5 demonstrated the most
reproducible repression of BM450697 in both Hep G2 and Hep 3B
Figure 3. siRNA Targeted Silencing of BM450697
(A) A schematic is shown depicting the tile of siRNAs
developed for both the BM450697 transcript and its
predicted promoter region. (B) siRNA screen targeting
both BM450697 transcripts and predicted promoter in
Hep G2 and Hep 3B cells. (C) siRNAs 4, 5, and p5
targeting of BM450697 resulted in activation of and a
decrease in BM450697 in siRNA-treated HepG2 and Hep
3B cells. (B and C) Data are representative of the
mean ± SD of three independent experiments with tripli-
cate treated conditions. The significance of differences
between two groups was determined by non-parametric
one-way ANOVA with the post hoc Dunn’s test (B) or by
two-way ANOVA with the post hoc Tukey’s test or Stu-
dent’s t test (C). *p < 0.05, **p < 0.01, and ***p < 0.0001.
www.moleculartherapy.org(Figures 3C and S3A) cells. We observed an 30% reduction in
BM450697 expression levels compared with the scrambled control
with both 5 and p5 siRNAs in Hep3B cells. In addition, p5 resulted
in a signiﬁcant decrease in BM450697 levels in Hep G2 cells (Fig-
ure 3C). Using intron-exon spanning primers, we observed that si5
and p5 increased nascent LDLR mRNA transcripts (Figure 3C). It
has also been established that LDLR levels are regulated, in part, by
a negative-feedback loop that increases PCSK9 levels.17 Thus, we
wanted to determine whether knockdown of BM450697 increases
PCSK9 mRNA levels. We found that siRNA 5 and p5 did not signif-
icantly increase PCSK9 mRNA levels (Figure S3B). Collectively, these
data, juxtaposed with those presented in Figures 1 and 2 and observed
by others,24 suggest that BM450697 is a transcriptional regulator of
LDLR and can therefore serve as a convenient and potentially highly
speciﬁc target to control LDLR expression via directed small RNAs.
siRNA p5 May Function to Transcriptionally Control BM450697
Expression
We next wanted to elucidate whether any of these siRNAs that target
BM450697 and result in the increase of LDLR mRNA expression
levels are functional, by initiating TGS26 of BM450697. Using the
ZENBU browser (http://fantom.gsc.riken.jp/zenbu) and the data
obtained from Matsui et al.,24 we found that several of our target
siRNAs were within potentially important transcriptional regions
for BM450697 expression (Figure S2). Thus, we performed both
trichostatin A (TSA) and 50 azacytidine (50 aza) experiments after
siRNA treatment. TSA inhibits multiple histone deacetylases
(HDACs), and whereas 50 aza inhibits DNA methyltransferase activ-
ity, both histone and DNA-methylation-associated proteins haveMolecular Therapbeen thought to be involved in the TGS
pathway.26 Interestingly, siRNA 5 and p5, were
found to be resistant to TSA treatment (Figures
4A and 4B), whereas the siRNA-mediated
effects on LDLR mRNA levels were lost when
treated with 50 aza in Hep 3B cells (Figure 4C).
To conﬁrm the 50 aza ﬁndings, we performed
a ChIP assay to determine whether there was
an enrichment of the methylation markerH3K27me3 at the siRNA target site (Figure 4D and S5). We observed
a signiﬁcant increase in H3K27me3 at the p5 target site in the
p5-transfected condition after 72 h, whereas no increase in
H3K27me3 was observed at the LDLR promoter site (Figure S4).
Further, when assessing the effects of 50 aza on BM450697 mRNA
expression, both si-5 and p5 silencing of the lncRNA were abrogated
in the presence of 50 aza (Figure 4E). Taken together, our data suggest
that we may be able to direct TGS to the promoter region for
BM450697 (Figure 4C), which controls LDLR expression and, ulti-
mately, LDL uptake by the liver.
siRNA-GalNAc Conjugates Gal-5 and -p5 Functions to
Transcriptionally Control BM450697 Expression and
Subsequently LDL Uptake in Hep 3B Cells
All natural 5 and p5 siRNAs were converted into their corresponding
therapeutic analogs by insertion of 20-OMethyl (20-OMe) on the sugar
moiety and phosphorothioate (PS) linkages in the backbone. Further-
more, the sense (S) strands of each pair were modiﬁed with GalNAc
on the 30 end to yield the corresponding modiﬁed siRNA-GalNAc
conjugates of 5 and p5, i.e., Gal-5 and Gal-p5 (Table 1), respectively.
The unconjugated controls (CTRL-5 and CTRL-p5) contained a free
alkyne on the 30 end, as designated in Table 1. It has been well estab-
lished in the literature that GalNAcs are readily recognized and taken
up by the asialoglycoprotein receptor (ASGPR) in hepatocytes.31
Upon ligand binding, the ASGPRs are endocytosed, whereupon the
receptor is recycled back to the surface of the cell, after which the ther-
apeutic siRNA can exert its function through the RNA interference
(RNAi) pathway or association with argonaute 1 (AGO1) complexes,
in the cell.26,31 Dosing of the siRNA conjugates showed that bothy: Nucleic Acids Vol. 17 September 2019 267
Figure 4. siRNA p5 Functions in a Transcription-
Silencing Manner
Hep 3B or Hep G2 cells were transfected with 50 nM
siRNAs and co-incubated with DMSO or either (A and B)
40 nM trichostatin A (TSA) or (C and E) 7.5 mM 50 azacy-
tidine. (A and C) Hep 3B and (B) Hep G2 cells were har-
vested 72 h later and assessed for LDLR expression by
qRT-PCR. (D) Hep 3B cells were transfected with 100 nM
p5 and processed for ChIP with H3K27me3 or its mouse
IgG control. DNA elutes were amplified with primers
toward the target region of p5 or with an off-target primer
set, located 8 kb upstream of the LDLR promoter in the
LDLR gene. (E) Hep 3B treated with 7.5 mM 50 azacytidine
were harvested 72 h later and assessed for BM450697
expression by qRT-PCR. Data are the mean ± SD of three
(A and B) or two (C–E) independent experiments with
triplicate treated conditions. Two-way ANOVA (A–C) or
one-way ANOVA (D) with the post hoc Tukey’s test
was performed. *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001.
Molecular Therapy: Nucleic AcidsGal-5 and Gal-p5 had dose-dependent effects on LDLR mRNA and
BM450697 RNA expression, with 50 nM showing signiﬁcant effects
for BM450697 repression and LDLR activation (Figures 5A and
5B). In addition, Gal-p5 appeared to be more potent than Gal-5,
showing increased LDLR mRNA activation at 15 nM (Figure 5A).
However, signiﬁcant repression of BM450697 was observed only
with 50 nM treatment with Gal-p5 (Figures 5A and 5B). It may be
that a small reduction in the lncRNA is sufﬁcient to elicit observable
effects on LDLR mRNA expression, because of the low expression
levels of this lncRNA in the cell (Figure S1B). In addition, we found
a signiﬁcant (1.4-fold) increase in LDLR protein levels, with
50 nM Gal-p5 in Hep 3B cells (Figure 5C), suggesting that this con-
jugate increases both LDLRmRNA and protein levels in Hep 3B cells.
Upon validation of the siRNA-GalNAc conjugates, we next sought to
determine whether these siRNA conjugates had any physiological ef-
fect on cholesterol uptake in the Hep 3B cell line. We observed that
Gal-5 and Gal-p5 had signiﬁcantly higher levels of uptake than their
respective controls (unconjugated siRNAs of CTRL-5 and CTRL- p5;
Figures 5D and S7). The increased LDL uptake (Figure 5D) in the
Gal-5 and Gal-p5 conditions (1.3- and 1.4-fold, respectively) appear
to mimic the observed increase in LDLR protein levels in Figure 5C,
suggesting that the increase in uptake may be proportional to the
increase in LDLR protein levels. We observed similar effects when
transfecting Hep 3B cells with the natural siRNAs, 5 or p5, in Hep
3B cells (Figure S6). Furthermore, Gal-5 and -p5 had similar levels
of LDL uptake compared to 1 mM Lovastatin (the positive control).
Taken together, these data suggest that Gal-5 and Gal-p5 modulated
LDL uptake in this cell line model.
siRNA-GalNAc Conjugate Gal-p5 Increases LDLR mRNA
Expression in Primary Hepatocytes
Bolstered by our ﬁndings that Gal-p5 appeared to increase LDLR
mRNA levels, decrease BM450697 RNA levels, and increase LDL
uptake, we wanted to determine if some of these effects were evident268 Molecular Therapy: Nucleic Acids Vol. 17 September 2019in primary human hepatocytes. We observed that direct addition of
the Gal-p5 conjugate lead to an 2.9-fold increase in LDLR mRNA
expression, more so than the increase observed with the transfected
natural siRNA p5 (Figure 5E) after 48 h. However, further optimiza-
tions are needed to improve the transfection efﬁciency in primary
hepatocytes, as increased cytotoxicity related to the lipofectamine-
based reagent may have masked the results after 48 h.32 Although
these observations were not statistically signiﬁcant, the trend suggests
that the increase with Gal-p5 was similar to that with the positive
control, 1 mM Lovastatin (Figure 5E). These data suggest that
Gal-p5 is amenable to uptake in primary human hepatocytes and
may increase LDLR mRNA levels ex vivo.
DISCUSSION
Our understanding of gene regulation by RNAs has been rapidly ex-
panding. lncRNAs represent a class of RNAs that exert gene modula-
tory effects in both the nucleus and cytoplasm. Nuclear effects include
recruitment of chromatin remodelling factors to either repress or
de-repress gene expression, working as enhancer RNAs, through
transcriptional interference at the promoter site, or acting as a scaf-
fold for regulatory proteins at target sites in the DNA.33 BM450697
is a lncRNA described by Matsui et al.24 It is a 1450 nt transcript
that runs AS to the LDLR promoter. According to the coding poten-
tial calculator (CPC2), BM450697 has a coding potential of 0.16,
classifying this RNA as non-coding.34
Based on our ChIRP and DRIP ﬁndings, this lncRNA is associated
with the promoter of the LDLR gene in the form of DNA:RNA hy-
brids. We also determined that BM450697 is most likely to work
through transcriptional interference, by preventing either transcrip-
tional factor binding or Pol II binding to the promoter. Several studies
have observed the effects of cis-acting lncRNAs in mediating tran-
scriptional effects through interference. Martianov et al.35 observed
that a non-coding transcript, upstream of the dihydrofolate reductase
Table 1. Design of Candidate siRNAs-GalNAc Conjugates and Unconjugated Controls
Oligonucleotide Sequence (50/ 30) siRNA
5X-S
50-CGCGGCGAGGAGCAA
GGCGACUU-30-X
Gal-5 (5Gal-S:5-AS)
5Gal-S
50-CGCGGCGAGGAGCAA
GGCGACUU-30-GalNAc
CTRL-5 (5X-S:5-AS)
5-AS
50-GUCGCCUUGCUCCU
CGCCGCGUU-30
p5X-S
50-CCCUGUGGAGACUU
GGGGGACUU-30-X
Gal-p5 (p5Gal-S:p5-AS)
p5Gal-S
50-CCCUGUGGAGACUU
GGGGGACUU-30-GalNAc
CTRL-p5 (p5X-S:p5-AS)
p5-AS
50-GUCCCCCAAGUCU
CCACAGGGUU-30
S, sense; AS, antisense.
www.moleculartherapy.org(DHFR) gene, interacts directly with the promoter region to form sta-
ble DNA:RNA triple-helix hybrids, displacing Pol II and the basal
transcription initiation complex from the DHFR promoter. They
also observed that this non-coding transcript directly interacts with
the general transcription factor IIB, to mediate this repressive func-
tion on DHFR mRNA transcription. Martens et al.10 observed that
the ncRNA SRG1 in Saccharomyces cerevisiae represses D-3-phos-
phoglycerate dehydrogenase 1 (SER3) through SRG1 transcription
through the SER3 promoter, which leads to a displacement of tran-
scriptional activators and Pol II binding to the SER3 gene. Interest-
ingly, Latos et al.36 found that the lncRNA Airn causes silencing,
not through its lncRNA product, but rather through the transcription
of the lncRNA itself, which leads to the displacement of Pol II at the
promoter of the Igf2r gene. The data reported here demonstrated that
exogenously added BM450697 RNA led to a signiﬁcant decrease in
Pol II at the LDLR promoter. In addition, our ChIRP results suggest
that lncRNA BM45069 is associated directly with the 30 end of the
LDLR promoter, and our DRIP assay conﬁrmed the presence of an
DNA:RNA hybrid. It thus appears that our mechanism is most likely
to occur through an DNA:RNA triple helix or hybrid at the LDLR
promoter that interferes with Pol II binding, rather than by transcrip-
tional interference through lncRNA transcription, which would only
occur in cis.
Having established and expanded upon the role of BM450697 in LDLR
mRNA transcription, we next determined its suitability as a therapeu-
tic target. Targeting LDLR expression may offer a treatment for type IIfamilial hypercholesterolemia (FH)16 and ASCVD.1 Currently, statins
represent the ﬁrst-line strategy, targeting FH by increasing LDLR
levels. However, 2%–12% of those with FH are unable to tolerate
high-intensity statins because of the adverse effects associated with
statin use.37,38 Thus, an approach to directly targeting LDLR mRNA
transcription may offer a suitable alternative to those unable to use
statin therapy. Matsui et al.24 described that repressing BM450697
leads to a concomitant increase in LDLR expression, which we also
observed. We found that siRNAs 5 and p5 appeared to be the most
robust targets for LDLR expression and BM450697 silencing, and
both did not signiﬁcantly increase the expression in PCSK9 mRNA
levels. Further, we observed that p5 repressed BM450697 RNA through
a mechanism that may involve methylation related to the loss of the
p5 effect with 50 aza on both LDLR and BM450697 mRNA levels
and an increased recruitment of H3K27me3 to the genomic target
site of p5. The ﬁnding that siRNAs can mediate TGS through hetero-
chromatin modiﬁcation has been shown in several studies in yeast39,40
and in mammalian cells, either through AGO1 recruitment41,42 or
through DNA methyltransferase 3A (DNMT3A) association at the
target methylation site.26,43 Taken together, the observations presented
here suggest that p5 may be useful as an siRNA therapeutic that may
mediate long-term silencing events of lncRNA BM450697 that results
in stable activation of LDLR.
We converted siRNA 5 and p5 into therapeutically relevant con-
structs primed for liver targeting (Gal-5 and -p5), by using the
liver-speciﬁc GalNAc ligand as a targeting appendage attached toMolecular Therapy: Nucleic Acids Vol. 17 September 2019 269
Figure 5. Chemically Modified siRNA-GalNAc Conjugates Gal-5 and -p5 Significantly Increase LDLRmRNA Expression in Hep 3B and Primary Hepatocytes,
Decrease the lncRNA BM450697, and Increase LDL uptake in Hep 3B Cells
Hep 3B cells were seeded at a concentration of 100,000 cells/well. siRNA conjugates targeted toward the lncRNA (Gal-5 and Gal-p5) or their corresponding unconjugated
controls (CTRL-5 or CTRL-p5) were added to the cells at increasing concentrations (15, 25, and 50 nM). After 48 h, the cells were harvested for RNA and reverse transcribed
with either random hexamers (A) or a strand-specific primer (B). (A) Relative LDLRmRNA expression levels and (B) relative BM450697 mRNA expression levels. Each siRNA-
GalNAc conjugate was normalized to its respective unconjugated control with each concentration set to 1. Data are the mean ± SEM of three independent experiments,
performed in triplicate. (C) An LDLR ELISA was used to determine LDLR protein levels with 50 nM treated with galNAc-siRNA. (A) A two-way ANOVA with a post hoc Tukey
test was used; ***p < 0.001, ****p < 0.0001. (B) An unpaired Student’s t test (*p < 0.05, **p < 0.01) and (C) a non-parametric one-way ANOVA with a post hoc rank test
(*p < 0.05) were performed. (D) siRNA conjugates (50 nM) were added to Hep 3B cells, after which the medium was replaced with serum-free EMEM 48 h later. As controls,
Hep 3B cells were treated with 1 mM Lovastatin (replaced daily) and 100 nM heparin (30 min before the uptake assay). The cells were processed for LDL uptake 24 h after
medium change, using an LDL uptake assay kit. Images were captured with the Nikon ECLPSE TS100 fluorescence light microscope, and data were analyzed using ImageJ.
version 1.50i. Data represent the relative integrated density in three independent experiments, with three fields of view obtained for each experiment performed in triplicate.
Data are the mean ± SEM. A non-parametric one-way ANOVA, with the post hoc Dunn’s test was used for comparisons between two conditions; ***p < 0.001 and
****p < 0.0001. When assessing the effects of Gal-5 and Gal-p5 to Lovastatin and heparin alone, a and b denote statistical significance; p < 0.001. (E) Primary hepatocytes
were seeded at a concentration of 375,000 cells/well. Gal-p5 or its unconjugated control CTRL-p5 were added directly to the cells. Natural siRNAs (scrambled or p5) were
transfected with RNAiMAX, as a control. After 48 h, the cells were harvested for RNA and 50 ng RNA was used in a one-step quantitative real-time PCR reaction. Relative
LDLR mRNA expression levels Gal-5 or p5 was normalized to their respective unconjugated (CTRL-p5) or scrambled (Scr) control set to 1. Histograms are representative of
the mean ± SEM of three independent experiments, performed in duplicate or triplicate.
Molecular Therapy: Nucleic Acidsthe S strands of chemically modiﬁed versions of 5 and p5, to
collectively, improve resistance toward nuclease activity, without
increasing hepatotoxicity.44 The GalNAc moiety is recognized
with high afﬁnity by the ASGPR,45 exhibiting a turnover rate of
approximately 15 min in the Hep G2 cell line.46 As such, the GalNAc
conjugation of siRNAs has become an increasingly popular conjuga-
tion for liver-directed targets.31,45 Gal-5 and Gal-p5 led to an in-
crease in LDLR mRNA expression, while concomitantly decreasing
BM450697 RNA expression, suggesting that these siRNAs-GalNAc
conjugates exert their function in the cell and are delivered without
the aid of a transfection reagent. Gal-p5 also signiﬁcantly increased
LDLR protein levels. Gal-5 and -p5 also increased LDL uptake to a270 Molecular Therapy: Nucleic Acids Vol. 17 September 2019similar extent, as 1 mM Lovastatin and Gal-p5 appeared to increase
LDLR mRNA levels in primary hepatocytes. Collectively, the data
presented here suggest that targeting the lncRNA BM450697 with
GalNAc-conjugated siRNAs may offer a useful therapeutic
approach to LDL maintenance (see Figure 6). Conjugation of
GalNAc to siRNAs is a viable strategy for delivery of siRNAs into
the liver. A completed phase II clinical trial using a PCSK9-targeted
siRNA-GalNAc conjugate found that a single dose of 300 mg/person
led to sustained low levels of LDL in patients for 180 days.47 Repres-
sion of PCSK9 results in the increased retention of LDLR on the cell
surface because of the loss of PCSK9-targeted degradation of
LDLR.18 Zimmermann et al.48 used a GalNAc-conjugated
Figure 6. Schematic Showing the ProposedMechanism of BM450697 and the Proposed Effect of the Uptake of the siRNA-GalNAc Gal-p5 on BM450697 and
LDLR Expression in the Cells
BM450697 expression results in a decrease in LDLR mRNA expression in hepatocytes by decreasing the accessibility of the Pol II binding site in the LDLR promoter. Upon
GalNAc binding, the ASGPR is internalized into an endosome through endocytosis.31 Thereafter, the siRNA-GalNAc conjugate (Gal-p5) is processed and associates with
AGO1.26 Once in the nucleus, the AGO1-associated complex exerts targeted gene silencing on BM450697, resulting in the loss of BM450697 through targeted TGS and
H3k27me3 recruitment26 and an increase in LDLR mRNA expression. More LDLR protein is now processed and available in clathrin-coated pits located at the cell surface,
allowing for an increase in LDL uptake and LDLR recycling to the surface of the cell.17,20
www.moleculartherapy.orgtherapeutic siRNA, Revusiran, in a phase I clinical trial and found
that this subcutaneously administered conjugate was well tolerated
and reduced expression of its target transthyretin (TTR) by approx-
imately 90%, with a multiple-dose strategy. The researchers found
that the conjugate was well tolerated in humans and demonstrated
robust and efﬁcient knockdown of its target gene in vivo. However,
Fitzgerald et al.47 reported several mild-to-moderate side effects in
11%–15% of the population treated with the PCSK9 inhibitor.
Our strategy to target a lncRNA with a discreet expression proﬁle
and effect, may offer an alternative strategy to reduce off-target
effects that may result from targeting coding genes. However, this
remains to be determined. Future studies would need to include a
humanized-liver mouse or primate model to validate our ﬁndings
in an in vivo setting, as BM450697 appears, like other lncRNAs,29
to be conserved to humans and primates.25 In addition, the use of
humanized mouse models has been shown to better recapitulate
the effects of human hepatocyte function.49,50 Further, we would
need to validate the efﬁcacy, LDL uptake and dosing strategy, and
toxicity of our siRNA-GalNAc conjugate (Gal-p5) compared to
other commercially available cholesterol-lowering strategies in
different hepatic cell lines, as well as in primary human hepatocytes,
to determine its true value as a therapeutic agent.The results of our study suggest that targeting of lncRNAs
may result in positive therapeutic outcomes. Indeed, several re-
views26,44,45 and studies in atherosclerosis and cholesterol mainte-
nance12–14 have suggested that lncRNAs are viable targets that
have robust and pronounced effects when targeted through RNAi-
mediated strategies.21–23,51–53 Invariably, there will be challenges
in the delivery of RNAi-based therapeutics. However, the advent
of the GalNAc-conjugated siRNA has shown great promise in
liver-targeted diseases, with several GalNAc conjugates in phase I
and II clinical trials.31 Our approach in targeting the TGS of
BM450697 could be a promising strategy for long-term treatment
of FH and those with hypercholesterolemia, where fewer doses
of the siRNA-GalNAc conjugate are needed to maintain LDL
levels in vivo.
MATERIAL AND METHODS
Cell Lines and Primary Hepatocytes
The human hepatocellular carcinoma cell lines Hep G2 and Hep
3B (ATCC, Manassas, VA, USA) were cultured in Eagle’s minimal
essential medium (ATCC) supplemented with 10% fetal bovine
serum (GeminiBio, Sacramento, CA, USA) at 37C in a water-
jacket incubator. The cells were mycoplasma free and wereMolecular Therapy: Nucleic Acids Vol. 17 September 2019 271
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patocytes were purchased from Zen-Bio (Morrisville, NC, USA)
and processed according to the manufacturer’s instructions, using
human hepatocyte plating medium and human hepatocyte main-
tenance medium from the manufacturer (Zen-Bio). Primary
hepatocytes were plated onto collagen-I-treated, 24-well plates
purchased from Corning (Corning, NY, USA). The primary
hepatocytes maintained their morphology for the duration of
the study.
Antibodies, Plasmids, and All-Natural siRNAs
Pol II phosphorylated serine 5 C-terminal repeat domain
(CTD; ab5131) and its respective rabbit IgG control antibody
(ab171870), as well as mouse IgG controls (ab18413), were pur-
chased from Abcam (Cambridge, UK). SREBP1 chip grade anti-
body (sc-13551X) was purchased from Santa Cruz (Dallas, TX,
USA). S9.6 (MABE1095) was purchased from Merck Millipore
(Burlington, MA, USA). A BM450697 expression vector was syn-
thesized by GeneWiz (South Plainﬁeld, NJ, USA) in a pcDNA3.1+
backbone. Ten all-natural siRNAs, designed to target the lncRNA
BM450697 or its putative promoter region,30 were synthesized
by Integrated Technologies (Skokie, IL, USA). Based on initial
screening analysis, two siRNA pairs (5 and p5) were chosen for
further investigation.
Design of Modified siRNA-GalNAc Conjugates
Therapeutic siRNA Gal-5 and Gal-p5 (Table 1) were designed to
contain alternating 20-OMe sugar modiﬁcations, along with PS link-
ages in the 30 ends. Contrary to S strands bearing only a single PS link-
age at the GalNAc-modiﬁed 30 end, therapeutic AS strands were
modiﬁed with three PS linkages at the 30 end, to improve resistance
toward 30 exonuclease activity. Furthermore, AS strands were ﬂanked
at the 5 ends with two 30-OMe modiﬁcations to improve stability
toward 5 exonuclease, including alternating 20-OMe motifs for pro-
tection against endonucleases.49
Synthesis of 20-OH/20-OMe PO/PS siRNAs
The corresponding base- and backbone-modiﬁed versions of siRNA 5
and p5 were designed to also contain a serinol alkyne modiﬁer on
the 30 end of the S strands. Both pairs were synthesized in an
N-dimethyltryptamine (DMT)-off mode on the Expedite 8909
(Perspective Biosystems, Framingham, MA, USA). RNA phosphora-
midite reagents were purchased from Glen Research (Sterling, VA,
USA); other reagents for the oligonucleotide synthesis were obtained
from ABI Scientiﬁc (Sterling, VA, USA). The synthesis was carried
out in a 1 mmol scale using 30-alkyne-modiﬁer serinol CPG and
NittoPhase UnyLinker Solid Support.
After synthesis, the column was dried and emptied into a PCR-clean
vial (RNase and DNase free), together with ﬁlters, and incubated with
1 mL methylamine (33% in ethanol) at 65C for 2 h. The mixture was
allowed to reach room temperature and kept at 4C for an additional
30 min. The mixture was ﬁltered, evaporated, and treated with 100 mL
desilylation reagent (750 mL N-methyl-2-pyrrolidone, 375 mL272 Molecular Therapy: Nucleic Acids Vol. 17 September 2019triethylamine, and 500 mL triethylamine trihydroﬂuoride) on a ther-
momixer at 67C for 3 h. Then, 10 mL quenching reagent (10 mL of
3 M NaOAc and 10 mL diethyl dicarbonate) was added, followed by
the addition of 15 mL of 5 M NaClO4 and 10 mL of 3 M NaOAc.
Cold acetone (1 mL) was added to precipitate the oligonucleotides.
The vial was centrifuged at 1,000 rpm for 10 min and placed at 4C
for 30 min, and the supernatant was removed (washed three times).
The pellet was dried on a speed-vac, redissolved in MilliQ, and sub-
jected to ion exchange (IE) high-performance liquid chromatography
(HPLC), using a Dionex UltiMate 3000 LC System equipped with a
DNAPac PA-100 (9  250 mm; 0.5 M NaClO4, 5%–60% over
45 min; 0.25 M Tris-Cl [pH 8], 10% over 45 min; MilliQ water).
Collected fractions were combined and subjected to desalting column
chromatography (Illustra NAP-5; GE Healthcare), and the purity of
each oligonucleotide 5X-S, 5-AS, p5X-S, and p5-AS was conﬁrmed
by the analytical IE HPLC (>90% purity). The identity of oligonucle-
otides was conﬁrmed by MALDI-TOF mass spectrometry (MS;
Bruker MicroTOF-Q II mass spectrometer) in positive mode, using
3-hydroxypicolinic acid matrix (10 mg/mL 3-hydroxypicolinic
acid and 50 mM ammonium citrate in 70% aqueous acetonitrile).
MS-calculated/MS-found values ([M+H]+) were 5-AS; 7394/7393,
p5-AS; 7434/7432, 5X-S; 7930/7928, p5X-S; 7831/7830.
Synthesis of siRNA-GalNAc Conjugate S Strands
All reagents for the click reactions were obtained from Sigma-Aldrich
(St. Louis, MO, USA) and were used as received. All reagents were
prepared as fresh solutions in MilliQ water prior to setting up click
reactions. Conjugation with a-GalNAc-PEG3-azide (Sigma-Aldrich,
SMB00392) was carried out in an inert atmosphere (argon). A
solution of an alkyne-modiﬁed oligonucleotide 5X-S or p5X-S
(20 nmol, 12 mL) was added to 142 mL MilliQ water, after which
a-GalNAc-PEG3-azide (200 nmol, 7.6 mL), aminoguanidine hydro-
chloride (50 mM, 4 mL), triethylammonium acetate (TEAA) buffer
(1 M, pH 7.3, 20 mL), Cu(II) Tris((1-hydroxy-propyl-1H-1,2,3-tria-
zol-4-yl)methyl)amine (THPTA; 10 mM, 10 mL), and ascorbic acid
(50 mM, 4 mL) were added to get a total reaction volume of 200 mL.
The reaction was stirred at room temperature for 12 h, after which
the reaction mixture was subjected to gel ﬁltration using a NAP-5 Se-
phadex column (Illustra; GE Healthcare, Pittsburgh, PA, USA). Pu-
rity was conﬁrmed by the analytical IE HPLC at 20C or 60C above
90%). MS calculated/MS found values ([M+H]+): 5Gal-S, 8308/8306;
and p5Gal-S, 8210/8208.
ChIRP Assay
The ChIRP assay was performed as described by Chu et al.54,55 Brieﬂy,
100 million cells were used per condition for the assay. The cells were
harvested from 500 cm2 dishes in 1 PBS and cross-linked with 0.5%
methanol-free formaldehyde (Sigma-Aldrich) for 10 min, before
quenching the reaction with 0.125mMglycine for 5min at room tem-
perature. Cells were washed once with ice-cold 1 PBS (Ca and Mg
free; Thermo Fisher Scientiﬁc, Waltham, MA, USA) and resuspended
in 10 mL 1 radioimmunoprecipitation assay (RIPA) buffer (10 mM
Tris-Cl [pH 8.0], 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100,
0.1% SDS, and 40 mM NaCl) with 1 Halt Protease Inhibitor
www.moleculartherapy.orgCocktail and 0.02 vol SUPERase In RNase Inhibitor (Invitrogen). The
cells were resuspended with a 26G needle, and lysed at 4C for 45 min
on a rotator, and centrifuged at 10,000 g for 10 min at 4C. The su-
pernatant was removed, and the nuclei were resuspended in 1
micrococcal nuclease buffer (New England Biolabs). Two thousand
units micrococcal nuclease (MNase) was added and the nuclei sus-
pension was incubated at 37C for 20 min. The MNase reaction
was inhibited by using 0.1 vol 0.5 M EDTA. Nuclei were centrifuged
at 10,000 g for 10 min at 4C and resuspended in 1 mL nuclear lysis
buffer (1 PBS, 1% SDS, 1% NP-40, and 1% Na-deoxycholate with
1 Halt Protease Inhibitor and 0.02 vol SUPERase In RNase Inhibi-
tor), resuspended with a 26G needle, and rotated for 30 min at 4C.
The nuclei were subsequently sonicated for 10 cycles (30 s on and
30 s off), to rupture the nuclei, and centrifuged at 10,000  g for
10 min at 4C, to remove the debris. The supernatant was collected,
and 10% was collected as the input. The remainder of the nuclei lysate
was used in the ChIRP assay.
Lysates were pre-cleared using Dynabeads MyOne Streptavidin C1
(Invitrogen) for 2 h at 4C with rotation. Thereafter, biotinylated AS
oligonucleotides (ASOs) toward BM450697 (Table S1) and scrambled
biotinylated ASOs (Table S1) were used for each condition, to a ﬁnal
concentration of 1,200 pmol. Nuclei lysates were incubated in hybrid-
ization buffer (750 mMNaCl, 1% SDS, 50 mMTris-Cl [pH 7.0], 1 mM
EDTA, and 15% formamide) with 1 Halt Protease Inhibitor Cocktail
and 0.02 vol SUPERase In RNase Inhibitor. Hybridization occurred
overnight at 37C. Dynabeads MyOne Streptavidin C1 (Invitrogen)
were washed according to the manufacturer’s instructions and resus-
pended in nuclear lysis buffer. Then, 200 mL of the prepared magnetic
beads was used for each ChIRP condition. Magnetic beads were incu-
bated with the lysates for 30 min at 37Cwith rotation. The beads were
collected on a magnetic stand and washed ﬁve times with 2 saline
sodium citrate (SSC) buffer (Invitrogen) with 0.5% SDS.
DNA was eluted off the beads, using 100 mg RNase A (Thermo
Fisher Scientiﬁc) and 100 U RNase H (New England Biolabs) in
1 mL elution buffer (50 nM NaHCO3 and 1% SDS) at 37C for
30 min with rotation. Thereafter, the elutes were collected, treated
with proteinase K (New England Biolabs), and reverse cross-linked
overnight at 65C. DNA was isolated using the QIAGEN PCR puri-
ﬁcation kit.
The remainder of the reaction was used for RNA isolation with
QIAzol (QIAGEN, Hilden, Germany), followed by a TURBO DNase
treatment (Ambion, Invitrogen) for 30 min. Primer-speciﬁc RT
was performed using the Quantitect Reverse Transcription kit
(QIAGEN). qPCR was performed as previously described, using
primers for the LDLR promoter (DNA) as well as primers speciﬁc
for the lncRNA BM450697 (RNA; see Table S1 for the primer sets).
ChIP and DRIP Assay
LinearizedBM450697DNAor a lambdaDNAcontrolwere transcribed
using the Durascribe Synthesis Kit (Lucigen, Middleton, WI, USA).
Thereafter, the DNA-free 20F RNA was dephosphorylated with calf in-testinal phosphatase (New England Biolabs) for 30 min at 37C. The
RNA was subsequently puriﬁed with the RNA MEGAClear Kit
(Ambion, Invitrogen), according to the manufacturer’s instructions.
For the ChIP assay, 2 million Hep 3B cells were seeded onto 15 cm2
dishes. The next day, the cells were transfected with 10 nMBM450697
or the control lambda RNA or with 100 nM scrambled or p5 siRNA,
and the media were replaced 24 h later. After 24 (RNA) or 48 (siRNA)
h, the cells were cross-linked with 0.5% methanol-free formaldehyde
for 10 min, before the reaction was quenched with 0.125 mM glycine
for 5 min at room temperature. The cells were washed once with ice
cold 1 PBS and resuspended in 1 mL 1 RIPA buffer with 1 Halt
Protease Inhibitor Cocktail. They were resuspended with a 26G nee-
dle, lysed at 4C for 45 min on a rotator, and centrifuged at 10,000 g
for 10 min at 4C. The supernatant was removed, and the nuclei were
resuspended in 1 micrococcal nuclease buffer (New England Bio-
labs). Four hundred units of micrococcal nuclease (MNase) was
added, and the nuclei suspension was incubated at 37C for
20 min. The MNase reaction was inhibited using 0.1 vol 0.5 M
EDTA. The nuclei were centrifuged at 10,000  g for 10 min at
4C and resuspended in 1 mL nuclear lysis buffer (with 1 Halt Pro-
tease Inhibitor Cocktail), resuspended with a 26G needle, and rotated
for 30 min at 4C. The nuclei were subsequently sonicated for ﬁve cy-
cles (30 s on and 30 s off ), to rupture the nuclei, and centrifuged at
10,000  g for 10 min at 4C, to remove debris. The supernatant
was collected, and 10% was used as the input. MNase-digested lysates
were incubated with 2 mg antibody overnight with rotation at 4C.
Thereafter, 20 mL magnetic protein A/G beads (Thermo Fisher Scien-
tiﬁc) was added to the lysates for 2 h at 4C with rotation. Using a
magnetic rack, bound beads were washed four times with a high-
salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
Cl [pH 8.1], and 500 mM NaCl), one time with LiCl washing buffer
(0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA,
and 10 mM Tris-Cl [pH 8.1]), and one time with 1 Tris-EDTA
(TE) buffer (Ambion, Invitrogen). Samples were subsequently eluted
in 100 mL elution buffer (1% SDS and 0.1 M NaHCO3) for 20 min at
68C. The elutes were subjected to sequential RNase and proteinase K
digestion for 1 h at 37C, before reverse cross-linking overnight at
65C. DNA was isolated by using a PCR puriﬁcation kit (QIAGEN).
To analyze the ChIP data, qPCR was performed with a standard curve
in each run. The calculated concentrations were used to determine the
enrichment of the protein at the target DNA site, as a fraction of
input.
DRIP assays were performed according to Halász et al.56 Brieﬂy,
after treatment with either exogenously added 20F control or 20F
BM450697 or with 100 nM scrambled or siRNA p5, cells were har-
vested for DNA using the Maxwell RSC Cultured Cells DNA Kit
(Promega, Madison, WI, USA). Thereafter, cells were sonicated
for 10 cycles of 30 s on and 30 s off, to shear the DNA to approx-
imately 500 bp fragments. Thereafter, 5 mg DNA was used per
condition, with half of the samples treated with RNase H
(New England Biolabs) overnight at 37C. RNase H-treated sam-
ples were puriﬁed using the DNA Clean and Concentrator kitMolecular Therapy: Nucleic Acids Vol. 17 September 2019 273
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with the S9.6 antibody, which speciﬁcally recognizes DNA:RNA
hybrids (Merck Millipore), overnight at 4C in IP buffer
(50 mM HEPES/KOH [pH 7.5], 0.14 M NaCl, 5 mM EDTA, 1%
Triton X-100, and 0.1% Na-deoxycholate), after which pre-blocked
magnetic protein A/G beads were added for 2 h at 4C. Samples
were washed successively with 1 mL low-salt buffer (50 mM
HEPES/KOH [pH 7.5], 0.14 M NaCl, 5 mM EDTA [pH 8], 1%
Triton X-100, and 0.1% Na-deoxycholate), 1 mL high-salt buffer
(50 mM HEPES/KOH [pH 7.5], 0.5 M NaCl, 5 mM EDTA
[pH 8], 1% Triton X-100, and 0.1% Na-deoxycholate), 1 mL
LiCl washing buffer (10 mM Tris-HCl [pH 8], 0.25 M LiCl,
0.5% NP-40, 0.5% Na-deoxycholate, and 1 mM EDTA [pH 8]),
and two washes of 1 mL TE (100 mM Tris-HCl [pH 8] and
10 mM EDTA [pH 8]) at 4C. Thereafter, samples were eluted
with 100 mL elution buffer (50 mM Tris-HCl [pH 8], 10 mM
EDTA, and 1% SDS) for 15 min at 65C. After puriﬁcation, the
nucleic acids were cleaned with the DNA Clean and Concentrator
kit (Zymo Research, Irvine, CA, USA) in 30 mL TE buffer. The
recovered DNA was then analyzed by qPCR, as mentioned above.
RNA, cDNA, and Quantitative Real-Time PCR
Cells were transfected with siRNAs (1–5 and p1–p5) using Lipofect-
amine RNAiMAX (Invitrogen) in Opti-MEM (GIBCO, Invitrogen).
Brieﬂy, the diluted siRNAs in Opti-MEM were added to RNAiMAX
in Opti-MEM and incubated at room temperature for 20min. Hep 3B
cells were plated at a density of 75,000 cells/24-well plate and trans-
fected the next day with the duplex siRNAs, using 1.5 mL RNAiMAX
per condition. Hep G2 cells were reverse transfected at a density of
75,000 cells/24-well plate with 50 nM siRNA, using 2.4 mL RNAiMAX
per condition. The media were replaced the following day, and the
cells were harvested 72 h after transfection. In testing the modiﬁed
siRNA-GalNAc conjugates (CTRL-5, CTRL-p5, Gal-5, and Gal-p5),
the conjugates were added directly to the wells of either Hep 3B cells
or primary hepatocytes, in the absence of any transfection reagent.
Cells were harvested 48 h after transfection. RNA was isolated by us-
ing the SimplyRNA kit for RNA isolation (Promega), according to the
manufacturer’s instructions. cDNA was synthesized by reverse tran-
scribing 250 ng total RNA using the Quantitect Reverse Transcription
kit, which includes a genomic DNA-wipeout step (QIAGEN). Quan-
titative real-time PCR was performed with 2 Fast Universal qPCR
Mix (Kapa Biosystems, Wilmington, MA, USA), according to the
manufacturer’s instructions, on a Roche LightCycler 96 real-time
PCR system (Roche, Basel, Switzerland). Thermal cycling parameters
started with 3 min at 95C, followed by 40 cycles of 95C for 3 s and
60C for 30 s. Speciﬁcity of the PCR products was veriﬁed by melting-
curve analysis (primers used in this study can be found in Table S1).
To amplify BM450697, primer-speciﬁc RT was employed, with a
primer complementary to the 30 end of the lncRNA (see Table S1).
Thereafter, touchdown qPCR was performed with the BM450697
primer set, downstream of the RT-speciﬁc primer. Thermal cycling
parameters started with 3 min at 95C, with touchdown PCR from
70C to 60C for 10 cycles, followed by 40 cycles of 95C for 3 s
and 60C for 30 s.274 Molecular Therapy: Nucleic Acids Vol. 17 September 2019For primary hepatocytes LDLR and HPRT1 were ampliﬁed, using the
Luna Universal One-Step qRT-PCR kit (New England Biolabs).
Brieﬂy, 50 ng RNA was added to each ampliﬁcation reaction, with
the following thermal cycling parameters: 10 min at 55C for RT
and 1 min initial denaturation at 95C, followed by 40 cycles of
95C for 10 s and 60C for 30 s.
All data were analyzed by the 2DDCt method, calibrated to a reference
gene, and normalized to the scrambled-control- or control-treated
sample set to 1.
Poly(dT) Enrichment and Depletion
Ten million Hep 3B cells were used per experiment, and poly(dT)
RNA was selected for use with the Oligo(dT)25 Dynabeads magnetic
capture kit, according to the manufacturer’s instructions (Thermo
Fisher Scientiﬁc). The negative fraction was used as the poly(dT)-
depleted fraction. One microgram of RNA was converted to cDNA
in either BM450697-speciﬁc RT primer or with random hexamers,
using the Quantitect Reverse Transcription kit (QIAGEN). PCR
was performed as described above for BM450697 ampliﬁcation.
The PCR products were separated on a 1.5% 1 Tris-acetate-
EDTA (TAE) agarose gel at 100 V for 40 min and visualized using
a Bio-Rad EZ Imager (Bio-Rad, Hercules, CA, USA).
Subcellular Fractionation
Ten million Hep 3B cells were used per experiment, in duplicate,
according to the fractionation protocol for RNA by Gagnon et al.57
DNase-treated, total isolated RNA was converted to cDNA using
the Quantitect Reverse Transcription kit (QIAGEN) with random
hexamers or an RT-speciﬁc primer. In order to assess the quality
of the fractionation, qPCR was performed, amplifying known
nuclear (NEAT1) or cytoplasmic (HULC1) lncRNAs. BM450697
was ampliﬁed as described above (see Table S1 for primers). Rela-
tive amounts of each transcript were determined with a standard
curve with Hep 3B genomic DNA and described as nanograms
per reaction. The PCR products were separated on a 1.5%
1 TAE agarose gel at 100 V for 40 min with a Bio-Rad EZ Imager
(Bio-Rad).
TSA and 50 Aza Experiments
Hep 3B and Hep G2 cells were seeded at a density of 100,000 cells/
12-well plate, and transfected as previously described. Trichostatin
A (Merck Millipore) was added to Hep 3B cells at a ﬁnal concentra-
tion of 40 nM. The cells were harvested 72 h later for RNA, as previ-
ously described. 50 Aza (Sigma-Aldrich, St. Louis, MO) was added
daily to a ﬁnal concentration of 7.5 mM, and the cells were harvested
at 72 h for total RNA isolation.
LDL Uptake Assay
Hep 3B cells were seeded at a density of 75,000 cells/24-well plate.
The next day, modiﬁed conjugates (CTRL5, CTRL-p5, Gal-5, or
Gal-p5) were added directly to each well, whereas unmodiﬁed
siRNAs (scrambled, 5, or p5) were transfected using 1.5 mL
RNAiMAX per condition. Media were replaced at 48 h with
www.moleculartherapy.orgserum-free EMEM. The LDL uptake assay was performed accord-
ing to the manufacturer’s instructions, using BODIPY-LDL at
2.5 mg/mL LDL per well (Molecular Probes, Invitrogen) the next
day. Images were acquired with a Nikon ECLPSE TS100 ﬂuores-
cence light microscope. Images were acquired using Nikon NIS
Elements, and data were analyzed, using ImageJ, version 1.50i
(Wayne Rasband; NIH, Bethesda, MD, USA). Lovastatin (Insolu-
tion Lovastatin, sodium salt; CalBiochem, Merck Millipore) at
1 mM was used as a positive control, with the medium replaced
and fresh Lovastatin added each day. Heparin at 100 mg/mL was
used as the negative control to prevent LDL uptake and was added
30 min prior to the assay (Thermo Fisher Scientiﬁc).
LDLR ELISA
Hep 3B cells were seeded at a density of 75,000 cells/24-well plate. The
next day, modiﬁed conjugates (CTRL5, CTRL-p5, Gal-5, or Gal-p5)
were added directly to each well, and 72 h later, total protein was har-
vested using RIPA buffer. LDLR protein levels were determined with
a human LDLR Quantikine ELISA kit (R&D Systems, Minneapolis,
MN, USA), according to the manufacturer’s instructions. Absorbance
was measured on a Promega GloMax Explorer microplate reader
(Promega).
Statistical Analysis
All experiments were performed in triplicate, with at least two biolog-
ical experiments performed per data set. Graphing and statistical an-
alyses were performed using Prism for Windows, version 7.03
(GraphPad Software, La Jolla, CA, USA). For experiments with mul-
tiple comparisons, one- or two-way ANOVA (parametric or non-
parametric) was performed, with a post hoc Tukey’s, Dunnett’s, or
non-parametric Dunn’s test. Where only two groups were compared,
the two-tailed unpaired Student’s t-test was performed. Details of the
graphical representation, statistics used, and n values for each ﬁgure
are described in each legend.
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